NalbuphineBradycardia following an off-label use: case report

被引：0

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1753卷 / 1期

关键词：

D O I：

10.1007/s40278-019-62147-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：255 / 255

相关论文

共 50 条

[21] CatequentinibPneumothorax following off-label use: case report
[J]. Reactions Weekly, 2022, 1925 (1) : 158 - 158
[22] SirolimusPneumonia following off-label use: case report
[J]. Reactions Weekly, 2020, 1800 (1) : 269 - 269
[23] FelbamateNeutropenia following off-label use: case report
[J]. Reactions Weekly, 2020, 1803 (1) : 111 - 111
[24] GalcanezumabConstipation following off-label use: case report
[J]. Reactions Weekly, 2025, 2046 (1) : 169 - 169
[25] InsulinHypoglycaemia following off-label use: case report
[J]. Reactions Weekly, 2021, 1843 (1) : 204 - 204
[26] MethylprednisoloneFungaemia following an off-label use: case report
[J]. Reactions Weekly, 2022, 1899 (1) : 243 - 243
[27] BevacizumabCataract following off-label use: case report
[J]. Reactions Weekly, 2019, 1747 (1) : 63 - 63
[28] DapsoneMethaemoglobinaemia following off-label use: case report
[J]. Reactions Weekly, 2021, 1843 (1) : 130 - 130
[29] DaratumumabHypogammaglobulinemia following off-label use: case report
[J]. Reactions Weekly, 2020, 1802 (1) : 114 - 114
[30] CyproteroneMeningiomas following off-label use: case report
[J]. Reactions Weekly, 2021, 1849 (1) : 152 - 152

← 1 2 3 4 5 →